24/7 Market News Snapshot 20 October, 2025 – Citius Oncology, Inc. Common Stock (NASDAQ:CTOR)

October 20, 2025

DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:CTOR) are discussed in this article.
Citius Oncology, Inc. is experiencing a notable upswing, with its shares trading at approximately $1.907, marking a significant gain of 12.18% from the previous close of $1.700. Today’s trading volume is remarkable at 853.41K, highlighting increased investor interest in the company’s stock. Analysts are observing that Citius’s current price action positions it above last day’s closing price, potentially indicating a bullish market trend. Resistance levels are projected around $2.00, while support may lie near $1.80. Sustained trading momentum will be essential for the continuation of this upward trajectory.

In conjunction with these developments, Citius Oncology has officially secured a vital distribution services agreement with McKesson Corporation, a leading pharmaceutical distributor in the industry. This partnership allows McKesson to serve as an authorized distributor for LYMPHIR (denileukin diftitox-cxdl), an immunotherapy recently approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The collaboration completes Citius’s comprehensive U.S. distribution network, now inclusive of all three major pharmaceutical distributors, thus ensuring enhanced accessibility for healthcare providers and patients alike ahead of LYMPHIR’s anticipated commercial launch in the fourth quarter of 2025.

Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals, expressed that this agreement is a critical milestone in their U.S. distribution strategy. He emphasized that by partnering with top-tier distributors like McKesson, the company is reinforcing its commitment to making LYMPHIR available to the CTCL community, ultimately addressing the need for advanced treatment options. As Citius Oncology progresses with its commercialization strategies, including market access and patient education initiatives, this collaboration underscores the company’s dedication to improving outcomes for patients in oncology.

Related news for (CTOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.